Which T Cell Leaders Are Attending in 2026?
Uniting leaders in Immunology, Preclinical Development, Translational Research, Antibody Engineering, and Immuno-Oncology, the summit will tackle the field's toughest challenges, from optimising tumour selectivity and managing toxicity to enhancing T-cell fitness and improving TCE durability and efficacy.
A*Star
Ability Biotherapeutics
AstraZeneca
Biocytogen
Boehringer Ingelheim
Cullinan Therapeutics
Cytospire Therapeutics
Enara Bio
GemPharmatech
Genmab
GSK
Immatics
Immunocore
iOmx Therapeutics
LabGenius Therapeutics
Molecular Partners
Orion Pharma
Philochem
Roche
RoukenBio
RoukenBio
Sanofi
Sanofi
Scancell
Servier
Synolo Therapeutics
T-Cypher Bio
Triptych Therapeutics
UCB
Veraxa Biotech
Explore the Full Event Guide
- 24+ expert speakers from pioneering biotech and large pharma, including GSK, Cytospire Therapeutics, AstraZeneca, Cullinan Therapeutics, T-Cypher Bio, Immunocore, Synolo Therapeutics, Roche and more
- Gain in-depth data-driven insights into achieving selective targeting of tumour-specific antigens, novel engineering approaches and emerging opportunities for TCEs in oncology and autoimmune diseases
- 5 interactive workshops and panel discussions to solve challenges in resistance, T cell exhaustion and on-target/off-tissue tissue to accelerate more efficacious and potent TCEs towards the clinic
